ACADIA Pharmaceuticals Inc.
ACAD
Rang in aandelen
#4429
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aandeelprijs
$20.42
Marktkapitalisatie
$3.52B
Verandering (1 dag)
3.13%
Verandering (1 jaar)
-2.48%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Categorie
Healthcare
Aantal uitstaande aandelen voor ACADIA Pharmaceuticals Inc. (ACAD)
Aantal uitstaande aandelen per June 2026: 171.60M
Volgens de laatste financiële rapporten en de aandelenkoers van ACADIA Pharmaceuticals Inc. bedraagt het huidige aantal uitstaande aandelen 171.60M. Aan het einde van December 2023 had het bedrijf 163.82M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van ACADIA Pharmaceuticals Inc. (ACAD) van 2000 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 171.60M | 3.55% |
| 2024 | 165.72M | 1.16% |
| 2023 | 163.82M | 1.32% |
| 2022 | 161.68M | 0.74% |
| 2021 | 160.49M | 2.01% |
| 2020 | 157.33M | 6.88% |
| 2019 | 147.20M | 16.29% |
| 2018 | 126.58M | 3.25% |
| 2017 | 122.60M | 5.82% |
| 2016 | 115.86M | 15.13% |
| 2015 | 100.63M | 3.48% |
| 2014 | 97.25M | 13.46% |
| 2013 | 85.72M | 56.23% |
| 2012 | 54.87M | 5.14% |
| 2011 | 52.18M | 35.21% |
| 2010 | 38.59M | 2.98% |
| 2009 | 37.48M | 0.98% |
| 2008 | 37.11M | 5.40% |
| 2007 | 35.21M | 26.10% |
| 2006 | 27.92M | 26.84% |
| 2005 | 22.01M | 112.63% |
| 2004 | 10.35M | 609.62% |
| 2003 | 1.46M | 0.48% |
| 2002 | 1.45M | 20.20% |
| 2001 | 1.21M | 12.90% |
| 2000 | 1.07M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | 47.96% |
US
|
|
| 396.00M | 130.77% |
US
|
|
| 478.91M | 179.08% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.76% |
NL
|
